NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

Phase 2

Active, not recruiting

Conditions: Refractory Malignant Solid Neoplasm
Refractory Cholangiocarcinoma
Malignant Solid Neoplasm

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Ceralasertib
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Drug: Olaparib

First Posted Date: 2019-03-18

Last Posted Date: 2025-05-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT03878095

Locations: 🇺🇸
University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

and more 10 locations

Effects of Low Fat Versus Low Carbohydrate Diets on Energy Metabolism

Not Applicable

Completed

Conditions: Healthy
Healthy Volunteers

Interventions: Dietary Supplement: LCHF diet
Dietary Supplement: LFHC diet

First Posted Date: 2019-03-18

Last Posted Date: 2021-06-03

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 21

Registration Number: NCT03878108

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

Phase 2

Active, not recruiting

Conditions: NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor
Metastatic Malignant Solid Neoplasm
Advanced Malignant Solid Neoplasm
Unresectable Malignant Solid Neoplasm

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Other: Pharmacodynamic Study
Procedure: Positron Emission Tomography
Drug: Telaglenastat Hydrochloride

First Posted Date: 2019-03-13

Last Posted Date: 2025-05-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT03872427

Locations: 🇺🇸
The University of Kansas Cancer Center - Olathe, Olathe, Kansas, United States
🇺🇸
Mercy Hospital Pittsburg, Pittsburg, Kansas, United States
🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

and more 28 locations

A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

Phase 3

Recruiting

Conditions: Neurofibromatosis Type 1
Visual Pathway Glioma
Low Grade Glioma

Interventions: Drug: Carboplatin
Procedure: Magnetic Resonance Imaging
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Drug: Selumetinib Sulfate
Drug: Vincristine Sulfate

First Posted Date: 2019-03-12

Last Posted Date: 2025-06-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 165

Registration Number: NCT03871257

Locations: 🇺🇸
University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States
🇺🇸
Nemours Children's Hospital, Orlando, Florida, United States
🇺🇸
University of Illinois, Chicago, Illinois, United States

and more 259 locations

Study of Endocrine-Related Conditions and Physiology

Recruiting

Conditions: Endocrine Disease

First Posted Date: 2019-03-08

Last Posted Date: 2025-06-05

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 1000

Registration Number: NCT03867448

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Phase 2

Recruiting

Conditions: Bladder Mixed Adenocarcinoma
Bladder Clear Cell Adenocarcinoma
Bladder Small Cell Neuroendocrine Carcinoma
Invasive Bladder Giant Cell Urothelial Carcinoma
Invasive Bladder Lymphoepithelioma-Like Carcinoma
Invasive Bladder Urothelial Carcinoma
Metastatic Bladder Plasmacytoid Urothelial Carcinoma
Metastatic Bladder Sarcomatoid Urothelial Carcinoma
Metastatic Chromophobe Renal Cell Carcinoma
Metastatic Papillary Renal Cell Carcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Scan
Drug: Cabozantinib S-malate
Procedure: Computed Tomography
Procedure: Echocardiography Test
Biological: Ipilimumab
Procedure: Magnetic Resonance Imaging
Biological: Nivolumab
Procedure: Positron Emission Tomography

First Posted Date: 2019-03-07

Last Posted Date: 2025-06-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 314

Registration Number: NCT03866382

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States

and more 569 locations

Online Survey in Studying Smoking Attitudes and Behaviors Among Current Smokers

Completed

Conditions: Smoker

Interventions: Other: Survey Administration

First Posted Date: 2019-03-05

Last Posted Date: 2021-09-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1100

Registration Number: NCT03863795

Locations: 🇺🇸
NCI Division of Cancer Control and Population Sciences, Rockville, Maryland, United States

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Castrate Sensitive Prostate Cancer

Interventions: Drug: goserelin
Drug: Enzalutamide
Drug: Abiraterone
Drug: 18F-DCFPyL
Drug: Prednisone
Procedure: Radical Prostatectomy

First Posted Date: 2019-03-04

Last Posted Date: 2025-03-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT03860987

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma

Phase 1

Withdrawn

Conditions: Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma
t(11;14) Negative

Interventions: Drug: Dexamethasone
Drug: Ixazomib
Drug: Ixazomib Citrate
Drug: Venetoclax

First Posted Date: 2019-02-27

Last Posted Date: 2019-03-26

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT03856112

Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

Phase 1

Active, not recruiting

Conditions: Metastatic Urothelial Carcinoma
Stage III Bladder Cancer AJCC v8
Stage IV Bladder Cancer AJCC v8
Locally Advanced Urothelial Carcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Biological: Pembrolizumab
Drug: Tazemetostat

First Posted Date: 2019-02-26

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT03854474

Locations: 🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut, United States

and more 31 locations

Home Terms & Conditions Privacy Policy